Fineline Cube

Follow:
14436 Articles
Suzhou Ribo Life Science Completes Enrollment for Phase IIa Study of FXI-Targeted siRNA Drug RBD4059
CompanyDrug

Suzhou Ribo Life Science Completes Enrollment for Phase IIa Study of FXI-Targeted siRNA Drug RBD4059

Nanjing King-Friend Bio's Biosimilar Victoza Approved by FDA
CompanyDrug

Nanjing King-Friend Bio’s Biosimilar Victoza Approved by FDA

Bio-Sincerity Pharma-tech Gains NMPA Approval for BIOS-0618 in Obstructive Sleep Apnea
CompanyDrug

Bio-Sincerity Pharma-tech Gains NMPA Approval for BIOS-0618 in Obstructive Sleep Apnea

Duality Biotherapeutics Makes Hong Kong IPO Debut with ADC Pipeline
CompanyDeals

Duality Biotherapeutics Makes Hong Kong IPO Debut with ADC Pipeline

Santen's Tapcom Approved by China's NMPA for Glaucoma Treatment
CompanyDrug

Santen’s Tapcom Approved by China’s NMPA for Glaucoma Treatment

Peijia Medical's ReachTactile Robot Assists First Human TAVR Trial
CompanyMedical Device

Peijia Medical’s ReachTactile Robot Assists First Human TAVR Trial

Enhertu Approved by EC for Earlier-Line Treatment of HR+/HER2-low Breast Cancer
CompanyDrug

Enhertu Approved by EC for Earlier-Line Treatment of HR+/HER2-low Breast Cancer

Sino Biopharmaceutical's TQB2101 Receives NMPA Approval for Phase I Trial in Advanced Malignancies
CompanyDrug

Sino Biopharmaceutical’s TQB2101 Receives NMPA Approval for Phase I Trial in Advanced Malignancies

Hengrui Pharmaceuticals Gains NMPA Approval for HRS-6719 in Solid Tumors
CompanyDrug

Hengrui Pharmaceuticals Gains NMPA Approval for HRS-6719 in Solid Tumors

Sanofi's Rilzabrutinib Granted Orphan Drug Designation for Rare Diseases
CompanyDrug

Sanofi’s Rilzabrutinib Granted Orphan Drug Designation for Rare Diseases

Sunshine Guojian's SSGJ-627 Gains NMPA Approval for Ulcerative Colitis Trial
CompanyDrug

Sunshine Guojian’s SSGJ-627 Gains NMPA Approval for Ulcerative Colitis Trial

Sarepta and Roche Seek to Resume Elevidys Trials After EMA Halt
CompanyDrug

Sarepta and Roche Seek to Resume Elevidys Trials After EMA Halt